Cel-Sci Corporation (NYSEAMERICAN:CVM) Sees Large Growth in Short Interest

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 765,484 shares, an increase of 231.8% from the May 31st total of 230,679 shares. Approximately 4.9% of the shares of the stock are short sold. Based on an average trading volume of 346,077 shares, the short-interest ratio is currently 2.2 days.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. US Bancorp DE purchased a new position in Cel-Sci during the 3rd quarter valued at $80,000. HighTower Advisors LLC bought a new stake in shares of Cel-Sci in the fourth quarter worth approximately $53,000. HRT Financial LP purchased a new stake in Cel-Sci during the fourth quarter valued at $60,000. XTX Topco Ltd purchased a new stake in Cel-Sci during the fourth quarter valued at approximately $66,000. Finally, Renaissance Technologies LLC purchased a new stake in Cel-Sci in the fourth quarter worth about $81,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Cel-Sci Price Performance

Shares of Cel-Sci stock traded up $0.14 during trading on Friday, hitting $1.11. The stock had a trading volume of 327,202 shares, compared to its average volume of 366,994. The company has a current ratio of 0.60, a quick ratio of 0.54 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average is $1.82 and its 200 day moving average is $3.73. The firm has a market cap of $19.40 million, a price-to-earnings ratio of -0.11 and a beta of 0.54. Cel-Sci has a 12 month low of $0.89 and a 12 month high of $13.48.

Cel-Sci (NYSEAMERICAN:CVM) last announced its earnings results on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.